Loading...
AAV platform
We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.
LentiVector® platform
We have built a sector leading lentiviral delivery system, LentiVector® platform which is already used in commercially available treatments.
Overview
Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.
Get in touch
Press releases
26 July 2022
26 July 2022
Platform
Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.
Services
OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.
Latest annual report
